KALADRUG-R

New tools for monitoring drug resistance and treatment response in visceral leishmaniasis in the Indian subcontinent

 Coordinatore PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE 

 Organization address address: Nationalestraat 155
city: ANTWERPEN
postcode: 2000

contact info
Titolo: Ms.
Nome: Eva
Cognome: Mostmans
Email: send email
Telefono: +32 3 2476722
Fax: +32 3 2476223

 Nazionalità Coordinatore Belgium [BE]
 Totale costo 3˙972˙950 €
 EC contributo 2˙999˙998 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-B
 Funding Scheme CP-SICA
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-11-01   -   2013-04-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE

 Organization address address: Nationalestraat 155
city: ANTWERPEN
postcode: 2000

contact info
Titolo: Ms.
Nome: Eva
Cognome: Mostmans
Email: send email
Telefono: +32 3 2476722
Fax: +32 3 2476223

BE (ANTWERPEN) coordinator 0.00
2    BANARAS HINDU UNIVERSITY

 Organization address address: BHU
city: VARANASI
postcode: 221005

contact info
Titolo: Prof.
Nome: Shyam
Cognome: Sundar
Email: send email
Telefono: +91 542 2309493
Fax: +91 542 2367568

IN (VARANASI) participant 0.00
3    BP KOIRALA INSTITUTE OF HEALTH SCIENCES

 Organization address address: Ghopa
city: DHARAN

contact info
Titolo: Mr.
Nome: Nanda Kumar
Cognome: Thapa
Email: send email
Telefono: +977 25 520991
Fax: +977 25 520251

NP (DHARAN) participant 0.00
4    CHARITE - UNIVERSITAETSMEDIZIN BERLIN

 Organization address address: Chariteplatz 1
city: BERLIN
postcode: 10117

contact info
Titolo: Ms.
Nome: Eveline
Cognome: Fraessdorf
Email: send email
Telefono: +49 30 450576024
Fax: +49 30 450576024

DE (BERLIN) participant 0.00
5    COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH

 Organization address address: Anusandhan Bhawan, Rafi Marg 2
city: NEW DEHLI
postcode: 110001

contact info
Titolo: Mr.
Nome: Swapan Kumar
Cognome: Chaudhuri
Email: send email
Telefono: +91 33 2473 6793
Fax: +91 33 2473 5197

IN (NEW DEHLI) participant 0.00
6    EBERHARD KARLS UNIVERSITAET TUEBINGEN

 Organization address address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074

contact info
Titolo: Dr.
Nome: Martin
Cognome: Eichner
Email: send email
Telefono: +40 7071 2975905
Fax: +40 7071 295075

DE (TUEBINGEN) participant 0.00
7    GENOME RESEARCH LIMITED

 Organization address address: THE GIBBS BUILDING, EUSTON ROAD 215
city: LONDON
postcode: NW1 2BE

contact info
Titolo: Mr.
Nome: David
Cognome: Davison
Email: send email
Telefono: +44 1223 494937
Fax: +44 1223 494919

UK (LONDON) participant 0.00
8    Indian Council of Medical Research

 Organization address address: Ansari Nagar
city: New Delhi
postcode: 110029

contact info
Titolo: Dr.
Nome: Sunita
Cognome: Saxena
Email: send email
Telefono: +91 11 26165797
Fax: +91 11 26198401

IN (New Delhi) participant 0.00
9    UNIVERSITEIT ANTWERPEN

 Organization address address: PRINSSTRAAT 13
city: ANTWERPEN
postcode: 2000

contact info
Titolo: Ms.
Nome: Anne
Cognome: Adams
Email: send email
Telefono: +32 3 2653028
Fax: +32 3 2653011

BE (ANTWERPEN) participant 0.00
10    UNIVERSITY OF STRATHCLYDE

 Organization address address: Richmond Street 16
city: GLASGOW
postcode: G1 1XQ

contact info
Titolo: Mr.
Nome: Martin
Cognome: Gregory
Email: send email
Telefono: +44 141548 2524
Fax: +44 141552 4401

UK (GLASGOW) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

form    visceral    indian    sub    resistance    combination    donovani    monitoring    quality    years    continent    drug    effectiveness    azar    elimination    leishmania    infectious    neglected    drugs    clinical    leishmaniasis    patients    tools    supply    laboratory    treatment    calls    kala    regimens    promotion    diseases    vl    kaladrug    policy    disease      

 Obiettivo del progetto (Objective)

'Visceral leishmaniasis (VL), one of the most-neglected infectious diseases, has an annual incidence of 500,000 cases. Early treatment is a major pillar of the current program for VL elimination on the Indian sub-continent. However, the arsenal of available drugs is very limited, and their use is jeopardized by drug resistance. Combination regimens for VL are under clinical development, but it will take several more years to change the drug policy. Meanwhile, the effectiveness of current drugs needs to be safeguarded in order to cure patients and ensure unremitting sustainment of VL control. For this, the uninterrupted supply of quality drugs, the promotion of treatment compliance and, the monitoring of treatment effectiveness and of drug resistance will be pivotal. The latter demands improved knowledge and know-how, hence clinical and laboratory research are urgently needed to support the drug policy of the VL elimination program. The present multi-disciplinary proposal addresses these needs: we aim to develop, evaluate and disseminate new tools for the assessment of drug resistance in L. donovani as well as innovative methodologies for monitoring Kala-Azar treatment effectiveness under routine conditions.'

Introduzione (Teaser)

Visceral leishmaniasis is one of the most neglected infectious diseases. Timely and effective treatment is crucial to current elimination efforts on the Indian subcontinent.

Descrizione progetto (Article)

Visceral leishmaniasis (VL), sometimes known as kala-azar or black fever, is a severe form of leishmaniasis - a disease caused by protozoan parasites of the Leishmania variety. According to reports, it is the second-largest parasitic killer in the world (after malaria), responsible for some 500;000 cases each year worldwide. Several species of Leishmania are known to prompt the visceral form of the disease, including L. donovani and L. infantum.

Combating visceral leishmaniasis (VL) calls for improved drug availability, supply, administration, effectiveness and control. Even when given to sufferers, resistance to the drug causes further concern. For this reason, the effectiveness of drugs distributed has to be monitored and protected so that patients can be cured and VL brought under control.

Although clinical development of combination regimens for VL is progressing, it will be years before drug policy will bring about changes. 'New tools for monitoring drug resistance and treatment response in visceral leishmaniasis in the Indian sub-continent' (Kaladrug-R) aims to develop, evaluate and provide tools that can assess drug resistance in L. donovani. Successes in this effort will provide for a steady supply of quality drugs and promotion of appropriate treatment.

Monitoring the effectiveness of treatment and possible resistance to drugs fighting kala-azar calls for improved eradication programmes and know-how. Kaladrug-R is helping to organise clinical and laboratory research which are needed to support the drug policy underpinning any resulting VL elimination campaign.

Altri progetti dello stesso programma (FP7-HEALTH)

BALI (2011)

Biofilm Alliance

Read More  

AXLR8 (2010)

Accelerating the transition to a toxicity pathway-based paradigm for chemical safety assessment through internationally coordinated research and technology development

Read More  

HARP (2010)

Evaluation and impact of screening and treatment approaches for the prevention of cervical neoplasia in HIV-positive women in Burkina Faso and South Africa: HPV in Africa Research Partnership

Read More